Matches in SemOpenAlex for { <https://semopenalex.org/work/W4282931683> ?p ?o ?g. }
- W4282931683 endingPage "918" @default.
- W4282931683 startingPage "910" @default.
- W4282931683 abstract "Men with grade group 2 or 3 prostate cancer are often considered ineligible for active surveillance; some patients with grade group 2 prostate cancer who are managed with active surveillance will have early disease progression requiring radical therapy. This study aimed to investigate whether MRI-guided focused ultrasound focal therapy can safely reduce treatment burden for patients with localised grade group 2 or 3 intermediate-risk prostate cancer.In this single-arm, multicentre, phase 2b study conducted at eight health-care centres in the USA, we recruited men aged 50 years and older with unilateral, MRI-visible, primary, intermediate-risk, previously untreated prostate adenocarcinoma (prostate-specific antigen ≤20 ng/mL, grade group 2 or 3; tumour classification ≤T2) confirmed on combined biopsy (combining MRI-targeted and systematic biopsies). MRI-guided focused ultrasound energy, sequentially titrated to temperatures sufficient for tissue ablation (about 60-70°C), was delivered to the index lesion and a planned margin of 5 mm or more of normal tissue, using real-time magnetic resonance thermometry for intraoperative monitoring. Co-primary outcomes were oncological outcomes (absence of grade group 2 and higher cancer in the treated area at 6-month and 24-month combined biopsy; when 24-month biopsy data were not available and grade group 2 or higher cancer had occurred in the treated area at 6 months, the 6-month biopsy results were included in the final analysis) and safety (adverse events up to 24 months) in all patients enrolled in the study. This study is registered with ClinicalTrials.gov, NCT01657942, and is no longer recruiting.Between May 4, 2017, and Dec 21, 2018, we assessed 194 patients for eligibility and treated 101 patients with MRI-guided focused ultrasound. Median age was 63 years (IQR 58-67) and median concentration of prostate-specific antigen was 5·7 ng/mL (IQR 4·2-7·5). Most cancers were grade group 2 (79 [78%] of 101). At 24 months, 78 (88% [95% CI 79-94]) of 89 men had no evidence of grade group 2 or higher prostate cancer in the treated area. No grade 4 or grade 5 treatment-related adverse events were reported, and only one grade 3 adverse event (urinary tract infection) was reported. There were no treatment-related deaths.24-month biopsy outcomes show that MRI-guided focused ultrasound focal therapy is safe and effectively treats grade group 2 or 3 prostate cancer. These results support focal therapy for select patients and its use in comparative trials to determine if a tissue-preserving approach is effective in delaying or eliminating the need for radical whole-gland treatment in the long term.Insightec and the National Cancer Institute." @default.
- W4282931683 created "2022-06-16" @default.
- W4282931683 creator A5000304926 @default.
- W4282931683 creator A5012224683 @default.
- W4282931683 creator A5012951660 @default.
- W4282931683 creator A5014513524 @default.
- W4282931683 creator A5025886998 @default.
- W4282931683 creator A5034290481 @default.
- W4282931683 creator A5034663203 @default.
- W4282931683 creator A5034950092 @default.
- W4282931683 creator A5035902985 @default.
- W4282931683 creator A5038194257 @default.
- W4282931683 creator A5039495553 @default.
- W4282931683 creator A5051120030 @default.
- W4282931683 creator A5058617146 @default.
- W4282931683 creator A5065219412 @default.
- W4282931683 creator A5065938090 @default.
- W4282931683 creator A5068397348 @default.
- W4282931683 creator A5072104844 @default.
- W4282931683 creator A5074518172 @default.
- W4282931683 creator A5077545940 @default.
- W4282931683 creator A5082504366 @default.
- W4282931683 creator A5091484362 @default.
- W4282931683 date "2022-07-01" @default.
- W4282931683 modified "2023-10-13" @default.
- W4282931683 title "MRI-guided focused ultrasound focal therapy for patients with intermediate-risk prostate cancer: a phase 2b, multicentre study" @default.
- W4282931683 cites W1530771926 @default.
- W4282931683 cites W1663630120 @default.
- W4282931683 cites W1938383528 @default.
- W4282931683 cites W1950067960 @default.
- W4282931683 cites W2004909463 @default.
- W4282931683 cites W2086240335 @default.
- W4282931683 cites W2098816456 @default.
- W4282931683 cites W2129841792 @default.
- W4282931683 cites W2141198296 @default.
- W4282931683 cites W2143962930 @default.
- W4282931683 cites W2287642617 @default.
- W4282931683 cites W2621178808 @default.
- W4282931683 cites W2810125259 @default.
- W4282931683 cites W2911752256 @default.
- W4282931683 cites W2967754500 @default.
- W4282931683 cites W2990427812 @default.
- W4282931683 cites W2993539218 @default.
- W4282931683 cites W2999081098 @default.
- W4282931683 cites W3000681039 @default.
- W4282931683 cites W3022375004 @default.
- W4282931683 cites W3089473562 @default.
- W4282931683 cites W3168924500 @default.
- W4282931683 doi "https://doi.org/10.1016/s1470-2045(22)00251-0" @default.
- W4282931683 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35714666" @default.
- W4282931683 hasPublicationYear "2022" @default.
- W4282931683 type Work @default.
- W4282931683 citedByCount "22" @default.
- W4282931683 countsByYear W42829316832022 @default.
- W4282931683 countsByYear W42829316832023 @default.
- W4282931683 crossrefType "journal-article" @default.
- W4282931683 hasAuthorship W4282931683A5000304926 @default.
- W4282931683 hasAuthorship W4282931683A5012224683 @default.
- W4282931683 hasAuthorship W4282931683A5012951660 @default.
- W4282931683 hasAuthorship W4282931683A5014513524 @default.
- W4282931683 hasAuthorship W4282931683A5025886998 @default.
- W4282931683 hasAuthorship W4282931683A5034290481 @default.
- W4282931683 hasAuthorship W4282931683A5034663203 @default.
- W4282931683 hasAuthorship W4282931683A5034950092 @default.
- W4282931683 hasAuthorship W4282931683A5035902985 @default.
- W4282931683 hasAuthorship W4282931683A5038194257 @default.
- W4282931683 hasAuthorship W4282931683A5039495553 @default.
- W4282931683 hasAuthorship W4282931683A5051120030 @default.
- W4282931683 hasAuthorship W4282931683A5058617146 @default.
- W4282931683 hasAuthorship W4282931683A5065219412 @default.
- W4282931683 hasAuthorship W4282931683A5065938090 @default.
- W4282931683 hasAuthorship W4282931683A5068397348 @default.
- W4282931683 hasAuthorship W4282931683A5072104844 @default.
- W4282931683 hasAuthorship W4282931683A5074518172 @default.
- W4282931683 hasAuthorship W4282931683A5077545940 @default.
- W4282931683 hasAuthorship W4282931683A5082504366 @default.
- W4282931683 hasAuthorship W4282931683A5091484362 @default.
- W4282931683 hasBestOaLocation W42829316831 @default.
- W4282931683 hasConcept C121608353 @default.
- W4282931683 hasConcept C126322002 @default.
- W4282931683 hasConcept C126838900 @default.
- W4282931683 hasConcept C141071460 @default.
- W4282931683 hasConcept C143409427 @default.
- W4282931683 hasConcept C197934379 @default.
- W4282931683 hasConcept C2775934546 @default.
- W4282931683 hasConcept C2776235491 @default.
- W4282931683 hasConcept C2780192828 @default.
- W4282931683 hasConcept C2781217009 @default.
- W4282931683 hasConcept C71924100 @default.
- W4282931683 hasConceptScore W4282931683C121608353 @default.
- W4282931683 hasConceptScore W4282931683C126322002 @default.
- W4282931683 hasConceptScore W4282931683C126838900 @default.
- W4282931683 hasConceptScore W4282931683C141071460 @default.
- W4282931683 hasConceptScore W4282931683C143409427 @default.
- W4282931683 hasConceptScore W4282931683C197934379 @default.
- W4282931683 hasConceptScore W4282931683C2775934546 @default.
- W4282931683 hasConceptScore W4282931683C2776235491 @default.
- W4282931683 hasConceptScore W4282931683C2780192828 @default.